NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)

Summary

The National Institutes of Health (NIH) is soliciting applications under the StrokeNet program for clinical trials and biomarker studies focused on stroke treatment, recovery, and prevention. The opportunity uses the UG3/UH3 phased cooperative agreement mechanism, with clinical trials listed as optional. The program aims to advance research through the established NIH StrokeNet infrastructure. The funding opportunity is open for an extended two-year window from November 2024 through November 2026.

What they want

How they evaluate

Risks & flags

• Ultra-long response window (2 years) is typical for NIH Program Announcement with Review (PAR) mechanisms and is not itself a red flag, but narrow alignment to StrokeNet infrastructure may favor applicants already embedded in the StrokeNet network
• UG3/UH3 phased mechanism requires milestone-driven phase transition, which can disadvantage applicants without prior StrokeNet affiliation